Patents by Inventor Clark L. Anderson

Clark L. Anderson has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 6096311
    Abstract: Monoclonal antibodies which react specifically to Fc receptor of human effector cells are disclosed. Binding of the antibodies to the receptor is not blocked by human immunoglobulin G. The antibodies are useful for targeting human effector cells (e.g. macrophages) against a target cell (e.g. a cancer cell, an infectious agent, etc.) For this purpose, bifunctional antibodies or heteroantibodies can be constructed containing the binding region derived from an anti-Fc receptor antibody and the binding region of a target-specific antibody. Targeted effector cells can be used to kill target cells by cell mediated antibody dependent cytolysis.
    Type: Grant
    Filed: June 2, 1997
    Date of Patent: August 1, 2000
    Assignee: Medarex
    Inventors: Michael W. Fanger, Paul M. Guyre, Clark L. Anderson
  • Patent number: 5635600
    Abstract: Monoclonal antibodies which react specifically to Fc receptor of human effector cells IgG are disclosed. Binding of the antibodies to the receptor is not blocked by human immunoglobulin G. The antibodies are useful for targeting human effector cells (e.g. macrophages) against a target cell (e.g. a cancer cell, an infectious agent, etc.) For this purpose, bifunctional antibodies or heteroantibodies can be constructed containing the binding region derived from an anti-Fc receptor antibody and the binding region of a target-specific antibody. Targeted effector cells can be used to kill target cells by cell mediated antibody dependent cytolysis.
    Type: Grant
    Filed: December 27, 1994
    Date of Patent: June 3, 1997
    Assignee: Trustees of Dartmouth College
    Inventors: Michael W. Fanger, Paul M. Guyre, Clark L. Anderson
  • Patent number: 4954617
    Abstract: Monoclonal antibodies specific for the high affinity (72 K.D.) F.sub.c receptor on human monocytes are diclosed. The monoclonal antibodies do not block normal IgG binding to the receptor.
    Type: Grant
    Filed: July 1, 1987
    Date of Patent: September 4, 1990
    Assignee: Trustees of Dartmouth College
    Inventors: Michael W. Fanger, Paul M. Guyre, Clark L. Anderson